RUBY Insider Trading
RUBY | Market Equity
Comprehensive Trading Performance Summary
The investment history of corporate insiders at RUBY provides a unique lens into the internal conviction of the company's leadership. By analyzing SEC Form 4 filings, investors can track how directors and officers are allocating their own capital. High-conviction buying often signals that management believes the current market price significantly undervalues future growth prospects, while strategic selling might occur for personal liquidity or portfolio diversification. Monitoring these shifts in ownership is essential for understanding the alignment between management and shareholders in the Market Equity sector.
Transactions on Chart
Open Full Chart| Filing Date | Trade Date | Reporting Person | Relationship | Type | Price | Qty | Total, $ | Owned After | Change, % |
|---|---|---|---|---|---|---|---|---|---|
| 2023-02-28 02:08 | 2023-02-24 | Appelhans Dannielle | Officer - CEO and President | SELL | $0.13 | 10,385 | $1,323 | 0 | -100.0% |
| 2023-02-02 05:41 | 2023-02-01 | CAGNONI PABLO J | Director | SELL | $0.25 | 8,448 | $2,112 | 66,082 | -11.3% |
| 2023-02-02 05:40 | 2023-02-01 | Appelhans Dannielle | Officer - CEO and President | OPT+S | $0.25 | 3,878 | $970 | 10,385 | 0.0% |
| 2023-02-01 05:51 | 2023-01-31 | CAGNONI PABLO J | Director | OPT+S | $0.24 | 7,240 | $1,745 | 74,530 | 0.0% |
| 2023-02-01 05:50 | 2023-01-31 | Turka Laurence A. | Officer - Chief Scientific Officer | OPT+S | $0.24 | 2,593 | $622 | 18,391 | 0.0% |
| 2022-08-12 22:06 | 2022-08-10 | Appelhans Dannielle | Officer - Chief Operating Officer | OPT+S | $0.80 | 5,737 | $4,590 | 6,763 | 0.0% |
| 2022-04-23 01:07 | 2022-04-21 | Epstein David R | Director | BUY | $1.44 | 30,000 | $43,329 | 4,720,012 | +0.6% |
| 2022-02-02 05:20 | 2022-02-01 | CAGNONI PABLO J | Director, Officer - CEO and President | OPT+S | $6.57 | 6,730 | $44,236 | 35,520 | 0.0% |
| 2022-02-02 05:19 | 2022-02-01 | Keson-Brookes Maiken | Officer - CLO & Corp. Secretary | OPT+S | $6.57 | 2,732 | $17,957 | 5,343 | 0.0% |
| 2022-02-02 05:18 | 2022-02-01 | Turka Laurence A. | Officer - Chief Scientific Officer | OPT+S | $6.57 | 2,517 | $16,544 | 4,921 | 0.0% |
| 2021-03-24 00:30 | 2021-03-19 | Flagship Ventures Fund IV General Partner LLC | 10% owner | BUY | $29.00 | 210,000 | $6,090,000 | 2,633,703 | +8.7% |
| 2021-03-16 03:28 | 2021-03-15 | Keson-Brookes Maiken | Officer - CLO & Corp. Secretary | OPT+S | $20.24 | 25,000 | $505,965 | 0 | 0.0% |
| 2021-02-17 05:51 | 2021-02-11 | Epstein David R | Director | SELL | $14.93 | 26,704 | $398,560 | 4,690,012 | -0.6% |
| 2021-02-11 05:12 | 2021-02-08 | Epstein David R | Director | SELL | $14.88 | 98,737 | $1,468,792 | 4,716,716 | -2.1% |
| 2020-04-24 23:13 | 2020-04-22 | Coughlin Christina M. | Officer - Chief Medical Officer | BUY | $5.52 | 19,000 | $104,814 | 19,000 | +100.0% |
| 2020-04-16 00:14 | 2020-04-14 | CAGNONI PABLO J | Director, Officer - CEO and President | BUY | $4.70 | 21,000 | $98,694 | 21,000 | +100.0% |
| 2020-03-20 01:34 | 2020-03-17 | Epstein David R | Director | BUY | $3.76 | 5,000 | $18,800 | 4,815,453 | +0.1% |
| 2020-03-18 00:59 | 2020-03-13 | Epstein David R | Director | BUY | $3.91 | 10,000 | $39,100 | 4,810,453 | +0.2% |
| 2019-12-19 03:50 | 2019-12-16 | CARPENTER CHRISTOPHER L. | Officer - Chief Medical Officer | OPT+S | $13.48 | 48,000 | $646,901 | 34,843 | 0.0% |
| 2019-10-17 13:01 | 2019-10-14 | LANGER ROBERT | Director | OPT+S | $8.52 | 7,500 | $63,875 | 0 | 0.0% |
| 2019-09-19 04:37 | 2019-09-16 | CARPENTER CHRISTOPHER L. | Officer - Chief Medical Officer | OPT+S | $10.11 | 48,000 | $485,208 | 34,843 | 0.0% |
| 2019-07-17 23:14 | 2019-07-15 | LANGER ROBERT | Director | OPT+S | $14.94 | 7,500 | $112,049 | 0 | 0.0% |
| 2019-06-25 01:02 | 2019-06-20 | CARPENTER CHRISTOPHER L. | Officer - Chief Medical Officer | OPT+S | $13.93 | 243 | $3,386 | 34,843 | 0.0% |
| 2019-06-20 04:39 | 2019-06-17 | CARPENTER CHRISTOPHER L. | Officer - Chief Medical Officer | OPT+S | $14.02 | 47,757 | $669,692 | 34,843 | 0.0% |
| 2019-04-18 03:42 | 2019-04-15 | LANGER ROBERT | Director | OPT+S | $17.57 | 7,500 | $131,799 | 0 | 0.0% |
| 2019-04-11 04:44 | 2019-04-08 | NISSEN TORBEN STRAIGHT | Officer - President | SELL | $20.00 | 2,100 | $42,000 | 1,845,304 | -0.1% |
| 2019-04-06 02:34 | 2019-04-03 | NISSEN TORBEN STRAIGHT | Officer - President | SELL | $20.00 | 12,596 | $251,920 | 1,847,404 | -0.7% |
| 2019-03-20 01:17 | 2019-03-15 | CARPENTER CHRISTOPHER L. | Officer - Chief Medical Officer | OPT+S | $15.84 | 48,000 | $760,114 | 34,843 | 0.0% |
| 2019-01-19 00:36 | 2019-01-14 | LANGER ROBERT | Director | OPT+S | $14.59 | 7,500 | $109,444 | 0 | 0.0% |
| 2018-07-23 23:34 | 2018-07-20 | Sohn Catherine A. | Director | BUY | $23.00 | 2,500 | $57,500 | 2,500 | +100.0% |
| 2018-07-23 23:33 | 2018-07-20 | Pomerantz Roger | Director | BUY | $23.00 | 100 | $2,300 | 100 | +100.0% |
| 2018-07-23 23:33 | 2018-07-20 | Cuss Francis M | Director | BUY | $23.00 | 10,000 | $230,000 | 10,000 | +100.0% |
| 2018-07-23 23:33 | 2018-07-20 | Symonds Jonathan | Director | BUY | $23.00 | 25,000 | $575,000 | 25,000 | +100.0% |
How to Interpret $RUBY Trades
Not every insider transaction in RUBY is a signal for immediate action. Professional investors look for "cluster buying"—when multiple executives simultaneously purchase $RUBY shares on the open market. It is crucial to distinguish between scheduled sales (under Rule 10b5-1) and voluntary increases in ownership, which demonstrate management’s true conviction that the stock is undervalued.
Data Source & Accuracy for RUBY
Insider activity data for RUBY is streamed in real-time directly from the SEC EDGAR system. We analyze raw Form 4 filings, filtering out technical adjustments and complex derivative transactions. This provides a transparent view of how ownership structure is evolving in $RUBY, allowing you to follow the capital of those with the most intimate knowledge of the company.
UNDERSTANDING THE DATA
FILING DATE: The date and time when the transaction was reported to the SEC. This is when the public first receives the information.
TRADE DATE: The actual day the insider executed the purchase or sale in the market.
INDUSTRY: The specific market sector the company operates in. Useful for identifying broader institutional capital flows across sectors.
OWNED AFTER: The total number of shares held by the insider following the transaction. This highlights the insider's remaining conviction in the company.
CHANGE %: The percentage increase or decrease of the insider's total position. Large percentage changes often carry more weight than the dollar amount alone.
TRADE TYPES DEFINITIONS
BUY: An open market purchase. Typically indicates an insider's belief that the stock is undervalued or poised for growth.
SELL: An open market sale. While often used for diversification or liquidity, large or unexpected sales can be a warning signal.
OPT+S (OPTION EXERCISE & SALE): This occurs when an insider exercises their stock options and sells them immediately. Often part of a structured compensation plan.